Format

Send to

Choose Destination
Lancet Respir Med. 2019 Mar;7(3):195-197. doi: 10.1016/S2213-2600(19)30036-0.

Towards optimal treatment for latent Mycobacterium tuberculosis infection.

Author information

1
University College London Institute for Global Health, University College London, London, UK.
2
Union Headquarters, International Union Against Tuberculosis and Lung Disease, Paris, France; Department of Medicine, Kenyatta University, Nairobi, Kenya.
3
Champalimaud Foundation, Centre for the Unknown, Avenida Brasília, Lisbon, Portugal.
4
Division of Infection and Immunity, Center for Clinical Microbiology, University College London, London, UK; National Institute of Health Research Biomedical Research Centre, University College London Hospitals, London NW1 2PG, UK. Electronic address: a.zumla@ucl.ac.uk.

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center